NeuBase stock rises on gene editing research collaboration
seekingalpha.com
finance
2022-10-21 12:52:06

PhonlamaiPhoto NeuBase Therapeutics (NASDAQ:NBSE) on Friday said it signed a gene editing research agreement with one of the top 10 global healthcare companies. The healthcare company will evaluate NeuBase's PATrOL technology for three monogenic genetic diseases. PATrOL is a peptide nucleic acid (PNA)-based technology aimed at editing, upregulating or downregulating gene function, NBSE said in press release on Friday. Under the agreement, the companies will collaborate on the evaluation of drug candidates for three undisclosed indications.
